# SUNOSI® (solriamfetol) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/solriamfetol

> The next catalyst for SUNOSI® (solriamfetol), sponsored by Axsome Therapeutics, Inc. (AXSM), is its primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | SUNOSI® (solriamfetol) |
| Codes |  |
| Sponsor | Axsome Therapeutics, Inc. (AXSM) https://sec-api.dev/companies/axsm/catalysts |
| Indications | mdd with eds symptoms, [prior inadequate response to oral cgrp inhibitors](https://sec-api.dev/indications/prior-inadequate-response-to-oral-cgrp-inhibitors), binge eating disorder taar1 = trace amine-associated receptor 1 1, [Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms](https://sec-api.dev/indications/major-depressive-disorder-with-excessive-daytime-sleepiness-symptoms), [Binge-Eating Disorder](https://sec-api.dev/indications/binge-eating-disorder), Excessive Sleepiness, [ADHD](https://sec-api.dev/indications/adhd) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Q1 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: prior inadequate response to oral CGRP inhibitors.
- First seen 2024-11-12, last confirmed 2025-02-18.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-021801): "NDA submission anticipated in 2H 2025 Topline results of FOCUS and PARADIGM Ph 3 trials of solriamfetol in ADHD and MDD, respectively, on track for 1Q 2025 Topline results from EMERGE Ph 3 trial of Symbravo in migraine in patients with prior inadequate response to oral CGRP inhibitors on track for 1Q 2025 Expanding commercial success Financial strength and operational excellence *Product revenue growth vs. comparable periods in 2023" https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "The Company anticipates completion of enrollment in the FOCUS trial in December 2024 and topline results in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "The Company anticipates completion of enrollment in the PARADIGM trial in the fourth quarter of 2024 and topline results in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "The Company anticipates topline results from the trial in 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "Topline results of FOCUS Phase 3 trial of solriamfetol in ADHD anticipated 1Q 2025" https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "Topline results of PARADIGM Phase 3 trial of solriamfetol in MDD anticipated 1Q 2025" https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "Solriamfetol (300 mg) Placebo 1:1 R Screening (5 weeks) Double-blind Phase (6 weeks) Follow-up (1 week) Baseline N=300 PARADIGM Phase 3 Trial Key eligibility criteria 18-65 years of age with confirmed diagnosis of moderate to severe MDD Primary endpoint Change from baseline in MADRS score The combination of monoamine reuptake inhibition and TAAR1/5-HT1A agonism showed synergistic results in two mouse models of depression1 Topline results from the PARADIGM Phase 3 trial of solriamfetol in MDD anticipated in 1Q 2025 EDS = excessive daytime sleepiness; MADRS = Montgomery-&Aring;sberg Depression Rating Scale 1." https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "(2021) Solriafemtol's dopamine, norepinephrine, and TAAR1 mechanisms appear relevant to the pathophysiology of BED1-3 Topline results from the ENGAGE Phase 3 trial of solriamfetol in binge eating disorder anticipated in 2025" https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-021801): "Topline results of FOCUS and PARADIGM Phase 3 trials of solriamfetol in ADHD and MDD, respectively, on track for 1Q 2025" https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_1.htm

### Mar 2025: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2025-05-05, last confirmed 2026-11-02.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063158): "Attention Deficit Hyperactivity Disorder: In March 2025, Axsome announced positive topline results from the FOCUS Phase 3 trial evaluating the efficacy and safety of solriamfetol in ADHD in adults." https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-443752): "In March 2025, we announced positive topline results from the FOCUS Phase 3 trial of solriamfetol in ADHD in adults." https://www.sec.gov/Archives/edgar/data/1579428/000119312526443752/axsm-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-342360): "In March 2025, we announced positive topline results from the FOCUS Phase 3 trial of solriamfetol in ADHD in adults." https://www.sec.gov/Archives/edgar/data/1579428/000119312526342360/axsm-20260630.htm

### 2H 2025: NDA/BLA submission

- Status: scheduled. Date confidence: half. Indication: prior inadequate response to oral CGRP inhibitors.
- First seen 2025-02-18, last confirmed 2025-02-18.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-021801): "NDA submission anticipated in 2H 2025 Topline results of FOCUS and PARADIGM Ph 3 trials of solriamfetol in ADHD and MDD, respectively, on track for 1Q 2025 Topline results from EMERGE Ph 3 trial of Symbravo in migraine in patients with prior inadequate response to oral CGRP inhibitors on track for 1Q 2025 Expanding commercial success Financial strength and operational excellence *Product revenue growth vs. comparable periods in 2023" https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_2.htm

### Q4 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-05-05, last confirmed 2025-11-03.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-261651): "Attention Deficit Hyperactivity Disorder: Axsome plans to initiate a Phase 3 trial of solriamfetol in children and adolescents with ADHD in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-261651): "Major Depressive Disorder with Excessive Daytime Sleepiness: Axsome plans to initiate a Phase 3 trial of solriamfetol in MDD patients with EDS in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-261651): "2019 Approximately 50% of patients with MDD also experience excessive daytime sleepiness (EDS)4, for which there are no approved treatments Initiation of Phase 3 trial of solriamfetol in MDD patients with EDS anticipated in 4Q 2025 Major depressive disorder (MDD) is one of the most common mental disorders in the U.S., impacting ~21M adults each year2,3" https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/axsm-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-101624): "Attention Deficit Hyperactivity Disorder: Axsome plans to initiate a Phase 3 trial of solriamfetol in children and adolescents with ADHD in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-101624): "Major Depressive Disorder: Axsome plans to initiate a Phase 3 trial of solriamfetol in MDD patients with excessive daytime sleepiness (EDS) in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-101624): "2019 Approximately 50% of patients with MDD also experience excessive daytime sleepiness (EDS)4, for which there are no approved treatments Initiation of Phase 3 trial of solriamfetol in MDD patients with EDS anticipated in 4Q 2025 Major depressive disorder (MDD) is one of the most common mental disorders in the U.S., impacting ~21M adults each year2,3" https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/axsm-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063158): "Initiation of Phase 3 trial of solriamfetol in major depressive disorder with excessive daytime sleepiness anticipated in 2025" https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063158): "The Company plans to initiate a Phase 3 trial of solriamfetol in ADHD in pediatric patients in 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063158): "The Company plans to initiate a Phase 3 trial of solriamfetol in MDD patients with EDS in 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-ex99_1.htm

### Feb 2026: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: MDD with EDS symptoms.
- First seen 2026-05-04, last confirmed 2026-11-02.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-202506): "Major Depressive Disorder: In February 2026, Axsome initiated the CLARITY study, a Phase 3, double-blind, placebo-controlled, multicenter, randomized withdrawal trial evaluating the efficacy and safety of solriamfetol for the treatment of MDD with EDS symptoms." https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/axsm-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-443752): "In February 2026, we initiated the CLARITY study, a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial of solriamfetol in patients with MDD with EDS symptoms." https://www.sec.gov/Archives/edgar/data/1579428/000119312526443752/axsm-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-342360): "In February 2026, we initiated the CLARITY study, a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial of solriamfetol in patients with MDD with EDS symptoms." https://www.sec.gov/Archives/edgar/data/1579428/000119312526342360/axsm-20260630.htm

### Q2 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-02-23, last confirmed 2026-05-04.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-202506): "Attention Deficit Hyperactivity Disorder: Axsome is on track to initiate two pediatric Phase 3 trials of solriamfetol in ADHD, one in children and one in adolescents, in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-062421): "Major Depressive Disorder with Excessive Daytime Sleepiness symptoms: Axsome is on track to initiate a Phase 3 trial of solriamfetol in MDD patients with EDS symptoms in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-ex99_1.htm

### 2H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3. Indication: binge eating disorder TAAR1 = Trace amine-associated receptor 1 1.
- First seen 2024-11-12, last confirmed 2026-05-04.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-261651): "Solriamfetol inhibits the reuptake of dopamine and norepinephrine, neurotransmitters implicated in the pathophysiology of binge eating disorder1-3 Topline results from the ENGAGE Phase 3 trial of solriamfetol in binge eating disorder anticipated in 2026 Pre-clinical and clinical data support potential effects of solriamfetol on appetite, food consumption, and weight4,5 Ongoing Phase 3 trial of solriamfetol in patients with binge eating disorder TAAR1 = Trace amine-associated receptor 1 1." https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/axsm-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063158): "Evaluating solriamfetol as a potential treatment for BED Solriamfetol (150 mg) Solriamfetol (300 mg) Placebo 1:1:1 R Screening (4 weeks) Double-blind Phase (12 weeks) Follow-up (1 week) Baseline ENGAGE Phase 3 Trial N=450 Key eligibility criteria 18-55 years of age with diagnosis of BED (DSM-5) Primary endpoint Change from baseline in days with binge eating episodes Solriafemtol's dopamine, norepinephrine, and TAAR1 mechanisms appear relevant to the pathophysiology of BED1-3 Topline results from the ENGAGE Phase 3 trial of solriamfetol in binge eating disorder anticipated in 2026 TAAR1 = Trace amine-associated receptor 1 1." https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-021801): "Evaluating solriamfetol as a potential treatment for BED Solriamfetol (150 mg) Solriamfetol (300 mg) Placebo 1:1:1 R Screening (4 weeks) Double-blind Phase (12 weeks) Follow-up (1 week) Baseline ENGAGE Phase 3 Trial N=450 Key eligibility criteria 18-55 years of age with diagnosis of BED (DSM-5) Primary endpoint Change from baseline in days with binge eating episodes Solriafemtol's dopamine, norepinephrine, and TAAR1 mechanisms appear relevant to the pathophysiology of BED1-3 Topline results from the ENGAGE Phase 3 trial of solriamfetol in binge eating disorder anticipated in 2026 TAAR1 = Trace amine-associated receptor 1 1." https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-202506): "The Company anticipates topline results from the ENGAGE Phase 3 trial in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-062421): "The Company anticipates topline results from the ENGAGE Phase 3 trial in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-261651): "The Company anticipates topline results from the ENGAGE Phase 3 trial in 2026." https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-261651): "The Company anticipates topline results from the SUSTAIN Phase 3 trial in 2026." https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-101624): "The Company anticipates topline results from the ENGAGE Phase 3 trial in 2026." https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-101624): "The Company anticipates topline results from the SUSTAIN Phase 3 trial in 2026." https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063158): "The Company anticipates topline results from the ENGAGE Phase 3 trial in 2026." https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063158): "The Company anticipates topline results from the SUSTAIN Phase 3 trial in 2026." https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "The Company anticipates topline results from the trial in 2026." https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Binge-Eating Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06413433 (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT06413433

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Excessive Sleepiness; Shift-work Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06568367 (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT06568367

### Q1 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Binge-Eating Disorder.
- First seen 2026-02-23, last confirmed 2026-11-16T22:20:01.192Z.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-442628): "Topline results anticipated 1Q 2027 Solriamfetol inhibits the reuptake of dopamine and norepinephrine, neurotransmitters implicated in the pathophysiology of binge eating disorder1-3 Preclinical and clinical data support potential effects of solriamfetol on appetite, food consumption, and weight4,5 1." https://www.sec.gov/Archives/edgar/data/1579428/000119312526442628/axsm-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-442628): "Target enrollment in the trial has been reached, and the Company anticipates topline results in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1579428/000119312526442628/axsm-ex99_1.htm
- ClinicalTrials.gov: "NCT06413433 (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT06413433
- ClinicalTrials.gov: "NCT06568367 (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT06568367
- Press release filed with the SEC (EX-99) (accession 0001193125-26-202506): "The Company anticipates topline results from the SUSTAIN Phase 3 trial in 2027." https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-062421): "Based on current enrollment trends, the Company anticipates topline results from the SUSTAIN Phase 3 trial in 2027." https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-341206): "The Company anticipates topline results from the SUSTAIN Phase 3 trial in 2027." https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Binge-Eating Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06878976 (A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT06878976

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Binge-Eating Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06878976 (A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT06878976

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: ADHD.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07773883 (An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07773883

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: ADHD.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07773883 (An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07773883

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: ADHD.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07717879 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07717879

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: ADHD.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07717892 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07717892

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: ADHD.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07717879 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07717879

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: ADHD.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07717892 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07717892

### December 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07484217 (Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07484217

### Dec 2028 to Mar 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07484217 (Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07484217

## Same indication

- [Ctx-1301 - dexmethylphenidate 6.25mg](https://sec-api.dev/pdufa/ctx-1301-dexmethylphenidate) (CING)
- [SYMBRAVO® (meloxicam-rizatriptan)](https://sec-api.dev/pdufa/meloxicam-rizatriptan) (AXSM)

Calendar months: [June 2028](https://sec-api.dev/fda-calendar/2028-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/solriamfetol.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SUNOSI® (solriamfetol) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/solriamfetol

```bibtex
@misc{secapidev_pdufa_solriamfetol_20261116,
  title        = {SUNOSI® (solriamfetol) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/solriamfetol}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_solriamfetol_20261116","title":"SUNOSI® (solriamfetol) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/solriamfetol","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
